CRSP - Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

2024-02-08 21:37:41 ET

Summary

• Intellia is adopting a distinct strategy by focusing on in-vivo gene editing, potentially redefining industry standards and expectations.
• Interim results from Intellia's in-vivo gene-editing program for ATTR amyloidosis show promising safety and efficacy profiles.
• Intellia is still a cash-burning company, while any commercial therapy is still some time away.

In our analysis of the CRISPR technology sector, particular attention has been paid to companies such as CRISPR AG ( CRSP ) and, more recently, Editas ( EDIT ). A critical aspect for these entities is the development of in-vivo programs. Success in this area not only promises enhanced scalability but also the potential for profitability. Historically, firms within this sector have opted for ex-vivo methodologies due to their simpler development processes, despite the challenges posed by scaling these operations....

For further details see: